EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds

Mai O Kadry iD, Rehab M Abdel-Megeed

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0302264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Mai O Kadry und 1 weiteren Autor:innen. Beteiligte Einrichtung: Therapeutic Chemistry Department, National Research Center, Al Bhoouth Street, Cairo, Egypt. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Liposomes, RNA, Long Noncoding, CRISPR-Cas Systems. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR/Cas9 is a recently discovered genomic editing technique that altered scientist’s sight in studying genes function. Cas9 is controlled via guide (g) RNAs, which match the DNA targeted in cleavage to modify the respective gene. The development in prostate cancer (PC) modeling directed not only to novel resources for recognizing the signaling pathways overriding prostate cell carcinoma, but it has also created a vast reservoir for complementary tools to examine therapies counteracting this type of cancer. Various cultured somatic rat models for prostate cancer have been developed that nearly mimic human prostate cancer. Nano-medicine can passively target cancer cells via increasing bioavailability and conjugation via specific legend, contributing to reduced systemic side-effects and increased efficacy. This article highlights liposomal loaded Nano-medicine as a potential treatment for prostate cancer and clarifies the CRISPR/Cas9 variation accompanied with prostate cancer. PC is induced experimentally in western rat model via ethinyl estradiol for 4 weeks and SC. dose of 3, 2’- dimethyl-4-aminobiphenyl estradiol (DAE) (50mg/kg) followed by treatment via targeted liposomal-coated compounds such as liposomal dexamethasone (DXM), liposomal doxorubicin (DOX) and liposomal Turmeric (TUR) (3mg/kg IP) for four weeks in a comparative study to their non-targeted analogue dexamethasone, doxorubicin and Turmeric. 3, 2’- dimethyl-4-aminobiphenylestradiol elicit prostate cancer in western rats within 5 months. Simultaneous supplementations with these liposomal compounds influence on prostate cancer; tumor markers were investigated via prostate-specific antigen (PSA), Nitric oxide (NOX) and CRISPR/Cas9 gene editing. Several long non-coding RNAs were reported to be deregulated in prostate cell carcinoma, including MALAT1 . On the other hand, gene expression of apoptotic biomarkers focal adhesion kinase (AKT-1), phosphatidylinistol kinase (PI3K) and glycogen synthase kinase-3 (GSK-3) was also investigated and further confirming these results via histopathological examination. Liposomal loaded dexamethasone; doxorubicin and Turmeric can be considered as promising therapeutic agents for prostate cancer via modulating CRISPR/Cas9 gene editing and long non coding gene MALAT1 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsLiposomesRNA, Long NoncodingCRISPR-Cas SystemsMaleAnimalsRatsHumansGene Editing

Substanzen

LiposomesRNA, Long Noncoding

Autor:innen und Institutionen

  • Therapeutic Chemistry Department, National Research Center, Al Bhoouth Street, Cairo, Egypt.

ORCID-Profile: Mai O Kadry

Förderung

  • National Research Centre

Zitieren

APA

Kadry, M. O., & Abdel-Megeed, R. M. (2024). CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds. PLOS ONE. https://doi.org/10.1371/journal.pone.0302264

Vancouver

Kadry MO, Abdel-Megeed RM. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds. PLOS ONE. 2024. doi:10.1371/journal.pone.0302264

BibTeX
@article{Kadry2024,
  author = {Kadry, Mai O and Abdel-Megeed, Rehab M},
  title = {CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0302264}
}
Kostenlos starten →